Selective COX-2 inhibitors reduced pain-related interference with daily life after surgery

Design

Systematic review and meta-analysis of 38 randomised trials

Population

5,424 adults having surgery, given systemic perioperative selective COX-2 inhibitors or control

Primary outcome

Acute postoperative pain interference with daily living (Brief Pain Inventory, 0 to 10) within 1 month

Effect

Mean difference -1.1 (95% CI -1.4 to -0.8; moderate certainty)

This systematic review screened 9,071 citations and included 38 randomised trials (5,424 adults) comparing systemic perioperative selective COX-2 inhibitors with placebo, opioids or usual care. The primary outcome was pain interference with daily living in the first month, measured with multidimensional tools such as the Brief Pain Inventory, where 1.0 point on a 0 to 10 scale is the smallest important difference.

Selective COX-2 inhibitors reduced pain interference by 1.1 points (95% CI -1.4 to -0.8; seven trials; moderate certainty), a clinically meaningful amount. Chronic pain incidence was lower (OR 0.44, 95% CI 0.21 to 0.93; five trials; low certainty), with no clear effect on chronic pain intensity (one trial, very low certainty). Quality of Recovery-9 improved by 0.84 points (low certainty), and blood loss was 22 ml lower (low certainty). No differences were found in the adverse events examined: renal failure, gastrointestinal bleeding, impaired bone healing, myocardial infarction, stroke and death.

The benefits for chronic pain and recovery rest on few trials. The adverse-event comparisons may lack power to exclude rare harms, and patients' own cardiovascular and renal risk still matters.

• Consider a selective COX-2 inhibitor as part of multimodal analgesia where it is not contraindicated.
• Check cardiovascular, renal and gastrointestinal risk before prescribing; the trials may not detect rare harms.
• Measure pain interference with function, not only a resting pain score.
• Expect an average gain of about one point on a ten-point interference scale.
• Treat chronic pain and recovery benefits as hypotheses, given low-certainty evidence.

Why it matters

It shifts the question from whether pain scores fall to whether patients can function.

Don't overread it

Only seven trials contributed to the primary outcome, and adverse-event findings are low certainty; it does not show that these drugs are safe in high-risk patients.

The statistics, in plain English

A mean difference of -1.1 sits just beyond the 1.0-point threshold for a minimal important difference, and its interval reaches below it (-0.8). The benefit is therefore meaningful on average but modest, and may be small for some patients. Low certainty means further trials could change the estimate.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.